TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29972002
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (oral mecobalamin, 0.5 mg, 3 times a day for 3 weeks)
Study: 24485709
Drug: Active OIT
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active OIT (peanut flour; protein doses of 2-800 mg/day)
Study: 19234106
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (n = 15, control)
Study: 12881939
Drug: Daily exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily exposure to pacifiers
Study: 7860469
Drug: Albendazole 15
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 15 mg/kg bodyweight/day for 30 days
Study: 2064878
Drug: Fentanyl 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 4.5 micrograms ml‐1
Study: 2064878
Drug: Adrenaline 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline 4.5 micrograms ml‐1
Study: 2064878
Drug: Adrenaline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline plus fentanyl (4.5 micrograms ml‐1 of each)
Study: 7055401
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of tinidazole (1600 mg) and doxycycline (400 mg) before operation
Study: 31044556
Drug: Ultralow dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultralow dose CT (100 Sn kV and 96 mA)
Study: 31044556
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose CT (110 kV and 50 mA)
Study: 31522147
Drug: Conventional periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional periodontal treatment (quadrant scaling and root planing - Q-SRP)
Study: 27732056
Drug: Multispecies probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multispecies probiotic supplement, taken twice daily for 8 weeks.
Study: 22839109
Drug: Diesel combustion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diesel combustion particles inhaled during spontaneous breathing
Study: 19708629
Drug: Brace and
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brace and surgery treatment (BS group)
Study: 19708629
Drug: Surgery with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery with no brace treatment (S group)
Study: 15045532
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AB and BSM
Study: 11976463
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron therapy (335 mg of ferrous sulphate and 500 g folic acid)
Study: 11976463
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron therapy (335 mg of ferrous sulphate and 500 g folic acid)
Study: 11976463
Drug: Daily and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily and weekly iron therapy
Study: 8079014
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine treatment
Study: 31545388
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis based on patient-specific risk factors
Study: 31545388
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of anticoagulant therapy perioperatively
Study: 31545388
Drug: Topical emollients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical emollients and petroleum
Study: 13679688
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between Immunotherapy and Control
Study: 11203592
Drug: EDTA gel
DrugBank: Edetate sodium (DB13404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA gel
Study: 8385183
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ramipril with 12.5 mg HCT
Study: 8385183
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ramipril with 25 mg HCT
Study: 8385183
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ramipril with 12.5 mg HCT
Study: 8385183
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ramipril with 25 mg HCT
Study: 8385183
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with ramipril plus HCT
Study: 8385183
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg HCT
Study: 27871236
Drug: Dexmedetomidine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine administered after spinal anesthesia (Group A)
Study: 27871236
Drug: Dexmedetomidine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine administered before spinal anesthesia (Group B)
Study: 24814039
Drug: Magnesium chloride
Normalized name: Magnesium Chloride
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium chloride (30 mL of MgCl2 5% solution) once daily for 3 months
Study: 24814039
Drug: NaHCO3 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaHCO3 0.1% solution (control) once daily for 3 months
Study: 22739364
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (400 mg/day)
Study: 8529770
Drug: Danazol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (400 mg/day)
Study: 1686422
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg QAM
Study: 1686422
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg QHS
Study: 1686422
Drug: Cetirizine 5
Normalized name: cetirizine 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 5 mg BID
Study: 6119512
Drug: Erythromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (250 mg 6‐hourly for adults and 40 mg/kg daily for children)
Study: 26597740
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (500 mg/day elemental calcium)
Study: 23374761
Drug: Home-based occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based occupational therapy for 10 weeks delivered by trained occupational therapists.
Study: 23374761
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no occupational therapy during the study period).
Study: 9803586
Drug: AIK-C measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIK-C measles vaccine (4.0 log10pfu) administered at 6 months
Study: 9803586
Drug: Schwarz vaccine
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz vaccine (3.7 log10pfu) given at 9 months
Study: 7633972
Drug: Ticlopidine 250
Normalized name: ticlopidine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 250 mg bd
Study: 31010516
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy by vascular surgery
Study: 31010516
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy by interventional cardiology
Study: 31010516
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy by interventional radiology
Study: 31010516
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy by other specialties
Study: 28183564
Drug: Tramadol+paracetamol (Zaldiar;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol+paracetamol (Zaldiar; 325 mg paracetamol, 37.5 mg tramadol)
Study: 23708155
Drug: G‐CSF‐mediated stem
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF‐mediated stem cell mobilization, apheresis, and intramyocardial injection of 1 × 10(5) autologous CD34(+) cells/kg
Study: 23708155
Drug: G‐CSF‐mediated stem
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF‐mediated stem cell mobilization, apheresis, and intramyocardial placebo injection
Study: 11401931
Drug: Intravenous glycoprotein
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glycoprotein IIb/IIIa inhibitor (12 patients, 86%)
Study: 9040650
Drug: High-dose immunoglobulins
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose immunoglobulins (IVIg)
Study: 7510155
Drug: Albumin excretion
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin excretion (marker of glomerulum)
Study: 20876343
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg once daily with low-sodium diet
Study: 20876343
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg once daily with high-sodium diet
Study: 15937679
Drug: Triiodothyronine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triiodothyronine treatment (1 microg/kg IV bolus followed by 0.06 microg/kg/hr continuous perfusion)
Study: 15937679
Drug: Standard support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard support treatment (0.9% ClNa delivered over 270 min)
Study: 15937679
Drug: Triiodothyronine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triiodothyronine treatment
Study: 15937679
Drug: Standard support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard support treatment
Study: 15937679
Drug: Triiodothyronine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triiodothyronine treatment and Standard support treatment
Study: 8636743
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin (100 mg/m2) plus epidoxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2)
Study: 8636743
Drug: Low-dose cisplatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cisplatin (50 mg/m2) plus epidoxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2)
Study: 8636743
Drug: Low-dose cisplatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cisplatin (50 mg/m2)
Study: 1731134
Drug: DTP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP and PRP-T given at separate injection sites (group 2)
Study: 6147691
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic chemotherapy
Study: 6147691
Drug: Prophylactic chemotherapy
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic chemotherapy
Study: 21291037
Drug: Controlled ovarian
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled ovarian hyperstimulation (COH) treatment
Study: 18565634
Drug: Marlboro Lights
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marlboro Lights (ML)
Study: 12588385
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg three times a day for 2 weeks
Study: 12588385
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet three times a day for 2 weeks
Study: 11092773
Drug: Intravenous sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sedation with midazolam
Study: 11092773
Drug: Local anaesthesia
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthesia and intravenous sedation
Study: 29930161
Drug: Ramipril (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (6 mg/m2 per day)
Study: 29930161
Drug: Ramipril therapy
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril therapy with proteinuria reduction <30%
Study: 29930161
Drug: Ramipril therapy
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril therapy with proteinuria reduction 30%-60%
Study: 29930161
Drug: Ramipril therapy
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril therapy with proteinuria reduction >60%
Study: 25416925
Drug: Saline isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline isotonic solution
Study: 17386354
Drug: zofenopril (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: zofenopril (15 to 30 mg/d)
Study: 17386354
Drug: ramipril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril (2.5 to 5 mg/d)
Study: 10691158
Drug: Rosiglitazone 1
Normalized name: rosiglitazone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 1 mg plus sulphonylurea
Study: 10691158
Drug: Rosiglitazone 2
Normalized name: rosiglitazone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 2 mg plus sulphonylurea
Study: 3079939
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg GTN spray
Study: 3079939
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg GTN spray
Study: 3079939
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg GTN spray
Study: 3079939
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg sublingual GTN
Study: 31714954
Drug: Cotrimoxazole preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole preventive therapy (CPT) continued
Study: 31714954
Drug: Cotrimoxazole preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole preventive therapy (CPT) discontinued (placebo)
Study: 26740684
Drug: LNS intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LNS intervention groups (10 g, 20 g, 40 g)
Study: 22709949
Drug: 23vPPS vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23vPPS vaccine (Pneumovax(®))
Study: 22709949
Drug: inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactivated influenza vaccine (Fluarix(®))
Study: 15866560
Drug: Orlistat plus
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat plus CBTgsh (120 mg three times a day)
Study: 12570939
Drug: eptifibatide plus
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eptifibatide plus unfractionated heparin
Study: 10554416
Drug: Nisoldipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (10 mg/day for 2 weeks before surgery)
Study: 1858442
Drug: Ibuprofen 1800-2400
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 1800-2400 mg per day for 3 weeks
Study: 28052714
Drug: Rectal ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rectal ibuprofen
Study: 25884223
Drug: EMDR (seven
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMDR (seven weekly 90 minute sessions) + TAU
Study: 24229598
Drug: Probiotics (live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (live combined bifidobacterium and lactobacillus tablets)
Study: 24229598
Drug: Oral immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunoglobulin (anti‐rotavirus egg yolk immunoglobulin, IgY)
Study: 19935591
Drug: Intermittent pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pneumatic compression (IPC) therapy (1 hour/day for multiple sessions)
Study: 19440083
Drug: Olanzapine 40
Normalized name: olanzapine 405 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 40 mg/d
Study: 6110912
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy (nasal prongs for at least 15 h daily, usually at 2 l/min)
Study: 25796338
Drug: Bivalent HPV‐16/18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent HPV‐16/18 vaccine
Study: 25796338
Drug: Control Hepatitis‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Hepatitis‐A vaccine
Study: 22878782
Drug: PE given
Approvals — FDA: no, EMA: no, PMDA: no
Description: PE given 30 min after a liquid meal as 100-g yoghurt drink
Study: 15297848
Drug: CC (Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC (Conventional Chemotherapy)
Study: 11309010
Drug: Ropivacaine 1
Normalized name: ROPivacaine 1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 1 mg/ml plus fentanyl 2 microg/ml administered via patient-controlled epidural analgesia (PCEA)
Study: 11309010
Drug: Ropivacaine 1
Normalized name: ROPivacaine 1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 1 mg/ml plus fentanyl 2 microg/ml administered via continuous epidural infusion (CEI)
Study: 9389843
Drug: Tramadol 2
Normalized name: traMADol 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 2 mg kg‐1 in 0.9% saline (group T)
Study: 9389843
Drug: Bupivacaine 2
Normalized name: bupivacaine 29.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2 mg kg‐1 (group B)
Study: 3123153
Drug: latamoxef (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: latamoxef (4 g/day)
Study: 3123153
Drug: ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ceftriaxone (2 g/day)
Study: 3123153
Drug: cefotaxime (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefotaxime (4 g/day)
Study: 28585263
Drug: Interventional sialendoscopy
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interventional sialendoscopy followed by intraductal steroid irrigations (group A)
Study: 28031511
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TXA) 15 mg/kg 15 minutes prior to surgery
Study: 24158412
Drug: Appropriate antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate antibiotic use according to local hospital guidelines
Study: 24158412
Drug: Early intravenous-oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intravenous-oral switching
Study: 21180082
Drug: Qingkailing Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingkailing Injection (QKL) plus Ertong Qingfei oral liquid
Study: 21180082
Drug: Ribavirin injection
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin injection plus compound guaiacol potassium sulfonale oral solution
Study: 16084850
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg twice daily for 5 days
Study: 10537956
Drug: Palliative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative treatment with gemcitabine in combination with best supportive care
Study: 7301035
Drug: Tienilic acid
Normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tienilic acid (250 mg/day)
Study: 7301035
Drug: Chlorothiazide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorothiazide (500 mg/day)
Study: 22101900
Drug: High-dose (HD;
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (HD; 200 IU/kg/d)
Study: 22101900
Drug: Low-dose (LD;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose (LD; 50 IU/kg 3 times/week)
Study: 20421833
Drug: 5 mg·kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg·kg of anhydrous caffeine
Study: 20421833
Drug: 2 mg·kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg·kg of anhydrous caffeine
Study: 18291401
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol for prevention of PPH
Study: 15746793
Drug: Low-dose prednisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisone (control group)
Study: 15746793
Drug: Steroid withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid withdrawal (study group)
Study: 15746793
Drug: Steroid withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid withdrawal group (1 year follow-up)
Study: 8630596
Drug: High-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaled budesonide (1,600 micrograms/d)
Study: 8630596
Drug: Low-dose inhaled
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose inhaled budesonide (400 micrograms/d)
Study: 8630596
Drug: Oral theophylline
Normalized name: theophylline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline (600 mg/d)
Study: 2857611
Drug: Idazoxan (RX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idazoxan (RX 781094), an alpha 2-antagonist, administered at low intra-arterial doses
Study: 2857611
Drug: Idazoxan (RX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idazoxan (RX 781094), an alpha 2-antagonist, administered at higher doses
Study: 2857611
Drug: Compounds with
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compounds with mixed alpha 2- and alpha 1-antagonist properties
Study: 29582212
Drug: CSL112 (1.7,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL112 (1.7, 3.4, or 6.8 g)
Study: 27097165
Drug: Benralizumab 2
Normalized name: benralizumab 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab 2 mg
Study: 27097165
Drug: Benralizumab 20
Normalized name: benralizumab 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab 20 mg
Study: 22710579
Drug: Lactulose (Gp‐L,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (Gp‐L, 30 ml three times per day)